DR. HANNA MAARIT MOISANDER-JOYCE, M. D.

NEW YORK, NY

Research Active
Pediatrics - Pediatric Hematology-Oncology NPI registered 12+ years 2 publications 2022 – 2022 NPI: 1093135576
Pediatrics - Pediatric Hematology-Oncology
Immune Checkpoint InhibitorsCarcinoma, HepatocellularAtypical Hemolytic Uremic SyndromePancreatitisPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Practice Location

525 EAST 68TH STREET
NEW YORK, NY 10065

Phone: (212) 746-5454

What does HANNA MOISANDER-JOYCE research?

Dr. Hanna Moisander-Joyce studies the use of immune therapies, specifically immune checkpoint inhibitors like anti-PD1, to treat adolescents with liver cancer prior to liver transplantation. By shrinking the tumor before surgery, these therapies may improve the chances of a successful transplant. Her research centers around how these treatments can safely be integrated into the care of young patients, particularly in minimizing the risk of severe complications like graft rejection—where the body’s immune system attacks the transplanted liver.

Key findings

  • In a case study, a teenager with hepatocellular carcinoma experienced a stable liver graft after receiving anti-PD1 therapy prior to transplantation.
  • The patient did well post-transplant, suggesting that immune checkpoint inhibitors can be safely bridged to transplantation in select pediatric patients.
  • This case provides early evidence supporting the use of innovative cancer therapies in the context of organ transplantation.

Frequently asked questions

Does Dr. Moisander-Joyce study liver cancer?
Yes, she studies liver cancer, particularly in adolescents, and how to effectively treat it before liver transplantation.
What treatment methods does Dr. Moisander-Joyce research?
She researches the use of immune checkpoint inhibitors, such as anti-PD1, in the treatment of liver cancer.
Is Dr. Moisander-Joyce’s work relevant to pediatric patients needing a liver transplant?
Yes, her work focuses specifically on improving outcomes for pediatric patients with liver cancer undergoing transplantation.

Publications in plain English

Rare Presentation of Atypical Hemolytic Uremic Syndrome in a Child With Acute Lymphocytic Leukemia and Pancreatitis.

2022

Journal of pediatric hematology/oncology

Mahajan RG, Moisander Joyce H, Green N, Hijiya N, Jain NG

Plain English
This study looked at a rare condition called atypical hemolytic uremic syndrome (aHUS) in a child who had both acute lymphoblastic leukemia and pancreatitis after starting chemotherapy. The case highlighted that aHUS can happen alongside other serious health issues, which can lead to kidney injury, low platelet counts, and anemia. Understanding this connection is important because it helps improve diagnosis and treatment strategies for affected children. Who this helps: This helps doctors and healthcare providers working with pediatric cancer patients.

PubMed

Stable liver graft post anti-PD1 therapy as a bridge to transplantation in an adolescent with hepatocellular carcinoma.

2022

Pediatric transplantation

Kang E, Martinez M, Moisander-Joyce H, Saenger YM, Griesemer AD +4 more

Plain English
A teenager with liver cancer received immune checkpoint inhibitor therapy (anti-PD1) to shrink the tumor before a liver transplant. Despite concerns that this drug could trigger severe rejection after transplant, the graft remained stable and the patient did well. This case offers early evidence that checkpoint inhibitors may be safely bridged to transplantation in carefully selected pediatric patients.

PubMed

Frequent Co-Authors

Ruchi G Mahajan Hanna Moisander Joyce Nancy Green Nobuko Hijiya Namrata G Jain Elise Kang Mercedes Martinez Yvonne M Saenger Adam D Griesemer Tomoaki Kato

Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.